OR WAIT null SECS
March 08, 2023
Janssen has received a positive opinion from EMA for AKEEGA plus prednisone or prednisolone for the treatment of BRCA1/2 gene-mutated metastatic castration resistant prostate cancer.
March 06, 2023
The guidance is intended to build on the existing International Council for Harmonisation (ICH) quality guidance.
March 03, 2023
The new guidance provides detailed recommendations to drug developers with a target of helping to ensure that drug developers provide adequate information to assess potency at each stage of a product’s life cycle.
EnteroBiotix is harnessing the power of the microbiome to target an array of diseases.
March 02, 2023
Lilly will cap insulin prices for patients with and without insurance at $35 per month.
Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.
February 27, 2023
WHO is appealing for US $392 million to reach 12.9 million people with essential health assistance in 2023.
Orchard Therapeutics has announced an agreement which will enable reimbursed access to Libmeldy for all eligible MLD patients in Sweden.
February 24, 2023
Moderna will leverage Life Edit’s suite of gene editing technologies to advance development of in vivo gene editing therapies.
Sanofi’s once-weekly replacement therapy is FDA-approved for prevention and treatment of bleeding episodes in people with hemophilia A.